Galectin Announces Early Warrant Exercise by 10X Fund, Issues Update on Cash Position

Loading...
Loading...
Galectin Therapeutics
GALT
, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that 10X Fund has exercised 300,000 common stock purchase warrants of Galectin Therapeutics at $3 per share for total cash proceeds of $900,000. The warrants were scheduled to expire on February 12, 2014. Following this transaction, the Company's total cash position is approximately $10.29 million and the total outstanding common shares are approximately 17.97 million.
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...